Available online on 15.10.2025 at http://ajprd.com

Asian Journal of Pharmaceutical Research and Development

Open Access to Pharmaceutical and Medical Research

Open Access

Review Article

Pharmacovigilance: A Pillar of Modern Drug Safety

Korade Payal B, Khaire Rahul D, Kathale Ankita A, Sanke Lochani D, Bhandare Tejashwini S, Ghuge Samiksha K

Pravara Rural Education Society's College of Pharmacy (For Women) ,Chincholi, Nashik, 422102,(Maharashtra),India.

A B S T R A C T

Pharmacovigilance (PV) Is A Pivotal Discipline In Clinical Research And Public Health, Focusing On The Detection, Assessment, Understanding, And Prevention Of Adverse Drug Reactions (Adrs). While PV Systems Are Well-Developed In High-Income Countries, They Remain Underdeveloped In Low- And Middle-Income Regions Such As India. This Review Highlights The Historical Evolution, Current Practices, And Future Prospects Of Pharmacovigilance, Emphasizing The Role Of Post-Marketing Surveillance, Risk Management, Patient Safety, And Vaccine Monitoring. It Also Explores Cutting-Edge Developments Including The Integration Of Big Data, Artificial Intelligence, And Pharmacogenomics To Enhance Personalized Medicine And Real-World Evidence Analysis. Despite These Advances, PV Faces Numerous Challenges, Including Underreporting, Poor Data Quality, Regulatory Barriers, Misinformation, Limited Integration Of Real-World Data, And Ethical Concerns Surrounding Data Privacy. The Document Advocates For Robust Policy Support, Capacity Building, Digital Infrastructure Development, And Global Collaboration To Address These Limitations And Ensure Drug Safety Across Diverse Populations.

Key Words: Challenges, Drug safety, General Approches, Future prospectives, Pharmacovigilance.

A R T I C L E I N F O: Received 19 March 2025; Review Complete 05 May 2025; Accepted 12 August 2025. ; Available online 15 Oct. 2025

Cite this article as:

Korade P B, Khaire R D, Kathale A A, Sanke L D, Bhandare T S, Ghuge S K, Pharmacovigilance: A Pillar of Modern Drug Safety , Asian Journal of Pharmaceutical Research and Development. 2025; 13(5):60-68, DOI: http://dx.doi.org/10.22270/ajprd.v13i5.1626

*Address for Correspondence:

Korade Payal B, Pravara Rural Education Society's College of Pharmacy (For Women) ,Chincholi, Nashik, 422102,(Maharashtra),India.

INTRODUCTION:

Pharmacovigilance is a critical component of clinical research, involving the detection, evaluation, understanding, and prevention of adverse drug reactions. Pharmacovigilance is important both during clinical trials and post-marketing stages of a drug's life cycle.While highly developed in Western nations, pharmacovigilance in India is still in the making and relatively underdeveloped. India formally started contributing to international pharmacovigilance activities in 1998 by becoming a member of the Uppsala Monitoring Centre. Regulators, media, and consumers are now more aware of drug safety since then, particularly with respect to long- and short-term medication adverse effects. Adverse events are any unplanned medical events that occur during treatment, and adverse drug reactions (ADRs) are explicitly harmful and unwanted effects of drugs at therapeutic doses. Spontaneous reporting of ADRs is one of the most significant ways to identify safety issues early. Indian pharmaceutical firms have, of late, raised their investment in research and development. ADRs remain important causes of hospitalizations and fatalities, however. ADRs account for approximately 200,000 hospitalizations and 197,000 fatalities each year in the EU, costing society around €79 billions.

Historical Background:

Pharmacovigilance emerged as a reaction to large-scale drug-related catastrophes, highlighting the importance of systematic monitoring of drug safety. In the pre-20th century era, drug safety was in no way regulated or known. The turning point came with the sulphanilamide tragedy (1937), and the U.S. imposed premarket drug safety testing. This was subsequently succeeded by the thalidomide catastrophe (1957–1961), which resulted in birth malformations and triggered international regulatory reforms. The WHO introduced the Programme for International Drug Monitoring (PIDM) in 1968, with global ADR reporting coordinated by

the Uppsala Monitoring Centre (UMC). As the years passed, agencies such as the FDA and EMA enhanced pharmacovigilance by post-marketing surveillance and risk management. India entered WHO's program in 1998, started its National Pharmacovigilance Programme (2004), and subsequently created the Pharmacovigilance Programme of India (PvPI) in 2010. India has progressively developed its national ADR monitoring network.Recent advances in digital health technologies, artificial intelligence, and real-world data have made it easier to identify and prevent adverse drug reactions, rendering pharmacovigilance more proactive and patient-centric.



Figure 1: Pharmacovigilance

ROLE OF PHARMACOVIGILANCE AND DRUG SAFETY:

Pharmacovigilance and drug safety are critical disciplines to provide assurance of the safe and effective use of medicines during their lifecycle. These practices are designed to detect, evaluate, understand, and prevent adverse drug reactions (ADRs) and other drug-related issues, thus. Safeguarding public health and enhancing patient outcomes:

1. **Detection of Adverse Drug Reactions (ADRs)**: PV systems detect and track ADRs by spontaneous reporting, clinical trials, post-marketing surveillance, and electronic health records.
2. **Risk Assessment and Management:** Collected safety data are evaluated to determine risks associated with drugs. Effective risk minimization strategies are then formulated and implemented.
3. **Regulatory-Decision-Making:** Pharmacovigilance assists regulatory agencies (such as the FDA, EMA, and CDSCO) to make evidence-based decisions on drug approvals, labelling changes, restrictions, or withdrawals.
4. **Patient and Healthcare Professional Education:** PV raises patients' and prescribers' of drug safety and the need for reporting adverse events.
5. **Post-Marketing Surveillance**: Ongoing monitoring once a medicine has been approved on the market detects awareness uncommon or delayed effects not seen in clinical trials.
6. **Signal Detection and Evaluation:** PV applies sophisticated methods for early detection of safety signals (suspected safety issues) enabling early intervention.
7. **Support To Rational Use of Medicines:** Ensures that drugs are utilized appropriately, enhancing therapeutic benefits and reducing harm.
8. **International pharmacovigilance and Global Health:** Networks supports international partnership (e.g., WHO-Uppsala Monitoring Centre) for global safety data exchange and analysis.

General Approaches:

1. **Early Detection of Adverse Drug Reaction:** Adverse drug reactions (ADRs) pose significant threats to public health, resulting in millions of severe cases and thousands of deaths every year. Conventional detection with the help of post-marketing reports is less efficient for newly approved medicines because of limited information. To overcome this, a new framework of label propagation was designed that combines drug chemical structure similarities with FAERS data. This method improves the precision of ADR detection, particularly for drugs with low reports, and was confirmed with a large FAERS dataset, representing a major achievement in pharmacovigilance.
2. **Risk Management Planning:** In the EU, Risk Management Plans (RMPs) are required for new or modified drug marketing authorizations. The 2017 update of GVP Module V brought a more targeted, evidence-driven approach to managing safety issues. Janssen Pharmaceuticals applied this guideline through the

development of three decision algorithms to assess and streamline safety issues in RMPs. Through this strategy, listed concerns were notably decreased, with widespread acceptance among EU regulators. The resultant RMPs were better focused and stronger, improving the regulatory transparency and prioritizing only those safety issues requiring additional action.

3. **Clinical Research And Drug Development:** Clinical studies are an important contribution of pharmacovigilance by producing information regarding drug efficacy, tolerability, and safety through every step of development. During the pre-marketing stage, clinical trials determine adverse drug reactions (ADRs), assess the benefit-risk ratio, and determine safety benchmarks. Translational research backs this up through the identification of biomarkers and facilitating personalized medicine. During the post-marketing period, continued studies track long-term and unusual ADRs, and assess the efficacy of risk reduction efforts. Lastly, clinical study information feeds into pharmacovigilance systems such as FAERS and Surveillance, facilitating signal detection and regulatory action.

4. **Enhancing The Patient Safety:** Pharmacovigilance (PV) is an essential field that guarantees safety of medicinal products throughout the entire life cycle. It entails the recognition, evaluation, comprehension, and prevention of adverse drug reactions (ADRs) to safeguard public health and optimize therapeutic benefits. Identification is the initial process, depending on methods such as spontaneous reporting and electronic health records for capturing safety information. Good assessment then ensues with the help of standardized instruments (e.g., WHO causality criteria, Naranjo algorithm) and data mining to analyse ADRs and generate safety signals. Knowledge of ADR mechanisms—through pharmacokinetics, pharmacogenomics, and post-marketing research—permits scientists to reveal risk factors and enable personalized medicine. As a whole, PV is critical for evidence-based risk management and patient-focused care.

5. **Pharmacoeconomics and Policy Making:**

   Pharmacodynamics is an important aspect of pharmacovigilance and drug safety as it describes how drugs interact with the body and assists in the prediction of adverse drug reactions (ADRs). It assists in detecting mechanism based (Type A) ADRs, therapeutic index and safety margins understanding, and identification of off-target effects leading to unforeseen reactions. Pharmacodynamics variability also facilitates personalized medicine and risk stratification for safer use of drugs across various populations. Also, it aids in monitoring real-world dose-response relationships, enhancing post-marketing surveillance and dosing regimens.

6. **Vaccine Safety Monitoring:** Pharmacovigilance maintains vaccine safety by tracking adverse events following immunization (AEFI). It identifies, evaluates, and prevents side effects with the help of tools such as VAERS, Vigi Base, and national surveillance systems. Through the study of real-world data, it detects rare reactions, assesses the quality of vaccines, and informs safe use.

Future Prospective:

1. **Big Data and Real World Evidence:** Classical drug safety surveillance systems such as FAERS and Eudra Vigilance are plagued by issues of underreporting and signal delay. These are overcome by utilizing Electronic Health Records (EHRs) and medical literature as ancillary tools. EHRs provide timely, large-scale clinical data that aids in early detection and analysis of drug adverse events. Medical literature with peer-reviewed information, is extracted by methods such as natural language processing to identify drug safety signals. In combination, these methods enhance the efficacy, efficiency, and responsiveness of pharmacovigilance. Real-world evidence (RWE) and big data improve pharmacovigilance through the ability to detect risks related to drugs earlier using data such as from EHRs, insurance claims, and wearables. RWE optimizes post-marketing surveillance by detecting adverse drug reactions (ADRs) that do not appear in clinical trials. It enables individualized risk-benefit assessment with varied data types. Sophisticated analytics such as machine learning and NLP assist in identifying safety signals from big data, while regulatory agencies increasingly leverage RWE to support well-informed decision-making regarding drug safety and labelling.

2. **Integration of Ai and Machine Learning:** Conventional drug safety surveillance systems such as FAERS and Surveillance are hampered by underreporting and slow signal detection. These are overcome by utilizing Electronic Health Records (EHRs) and medical literature as add-on tools. EHRs provide actual-time, large-scale clinical information that aids early detection and examination of adverse drug events. Medical literature, with peer-reviewed information, is mined using methods such as natural language processing to identify drug safety signals. Collectively, these strategies enhance pharmacovigilance accuracy, efficiency, and responsiveness.Artificial intelligence, and especially machine learning (ML), improve pharmacovigilance through the forecasting of adverse drug reactions (ADRs), simulation of clinical trials, and enhanced analysis of data. ML identifies unforeseen ADRs based on mechanistic models and real-world evidence. It also assists in constructing external control arms for simulated trials to facilitate scenario-based risk analysis. It is essential to include prediction uncertainty since incorrect associations may undermine patient safety. AI technologies, such as NLP and deep learning, enhance processing of ICSRs, monitor ADRs on social media, and handle large data. In general, AI can enhance precision, automation, and productivity in drug safety monitoring. Nevertheless, challenges such as training expenses, time considerations, and data bias are still there. As the use of AI increases in healthcare facilities, it will be projected to play a central role in enhancing pharmacovigilance systems.

3. **Pharmacogenomics and Personified Medicine:** Pharmacogenomics the investigation of genetic

determinants of drug response is defining the future of pharmacovigilance by making personalized medicine possible. It enables risk prediction on an individual basis, tailored drug choice and dosing, and preventative prevention of adverse drug reactions (ADRs). Interfacing with big data and electronic health records (EHRs) facilitates real-time safety surveillance, while artificial intelligence (AI) and genomic analytics reveal new druggene interactions. In spite of its promise, there are obstacles such as expense, regulatory variation, and low genetic literacy that must be overcome. Pharmacogenomics overall will revolutionize pharmacovigilance as a more predictive, more precise, and more preventive science. Personalized medicine seeks to individualize treatment according to unique patient features including age, genetics, and biomarkers. Genomic progress pushes the goal of maximizing therapies in specific subpopulations or individuals. Genomic medicine, especially pharmacogenomics (investigation of how genes influence drug response), is key to this transformation.

4. **Expansion of Safety Monitoring to Biologics and Biosimilar:** The horizon of pharmacovigilance is expanding to include the growth in the utilization of biologics and biosimilar—large, complex therapeutic molecules produced from living sources. In contrast to conventional small-molecule therapies, biologics are heterogeneous in manufacture and structurally sensitive, which renders them more susceptible to immunogenicity and lot-tolot variability. This calls for increased and specialized pharmacovigilance measures. Biologics, including monoclonal antibodies, vaccines, and recombinant proteins, need post-marketing monitoring to ensure detection of late adverse effects, immunogenicity, and long-term safety. Biosimilar, although very similar to approved reference biologics, are not identical. Hence, effective comparative safety monitoring is needed to identify subtle differences in efficacy or safety profiles, particularly in extrapolated indications. Pharmacovigilance systems have been modified to encompass: Distinct product codes and traceability systems for unambiguous attribution of adverse drug reactions (ADRs).Biologicspecific Risk Management Plans (RMPs) (e.g., immunogenicity risk management).Active surveillance strategies and real-world evidence (RWE) collection to augment spontaneous reporting. Regulatory agencies like the EMA and FDA require stringent post-marketing surveillance systems for biologics and biosimilar, further enshrining pharmacovigilance as a basis of biologic drug safety. With increasing use of these agents in different therapeutic areas, continuous improvement of the safety monitoring instruments remains imperative to guarantee patient safety and therapeutic assurance.

Ethical and Privacy Consideration:

Pharmacovigilance entails the gathering, evaluation, and dissemination of health information to guarantee the safety of drugs, posing serious ethical as well as privacy issues. With pharmacovigilance systems utilizing electronic health records (EHRs), mobile health data, social media, and genomics more intensively, the danger of patient identifiable data exposure has grown stronger. The major ethical principles are: Informed consent: Spontaneous ADR reporting systems are usually not expected to obtain explicit consent, but large-scale data mining and active surveillance raise concerns about patient awareness and consent. Data minimization and anonymization: Pharmacovigilance systems should guarantee that only data relevant to pharmacovigilance purposes is collected and identifiers removed to the extent practicable in order to maintain confidentiality Transparency and accountability: Stakeholders should be open about collecting, storing, and using data. Patients are entitled to understand how their data helps to provide drug safety. Equity and non-discrimination: Ethical pharmacovigilance ensures that safety surveillance covers all groups in a population and does not disproportionately exclude vulnerable or marginalized ones.Legal systems like the EU's General Data Protection Regulation (GDPR) and the US's HIPAA regulate data privacy, and their requirements that pharmacovigilance activities be done according to high standards for data security, access control, and cross-border data transfer. In general, there has to be a balance between public health gain and privacy rights to ensure the ethical practice of pharmacovigilance in the age of big data and personalized medicine. Pharmacovigilance is important in post-marketing monitoring of drugs, but its application must follow strong ethical and privacy measures. Ethical behaviour protects data integrity and participants' rights in monitoring adverse drug reactions (ADR).Some of the major ethical principles are: Informed consent: Particularly in patient interactive studies, participants should be well informed about the intention, risks, benefits, and their rights, including withdrawal at any time.

Confidentiality and data protection: Preserving participant identity by anonymizing data and safe storage is imperative, in accordance with laws such as GDPR and Heparins-benefit analysis: Ongoing assessment should guarantee that the prospective advantages of a study are greater than its risks.

Vulnerable population protection: Studies on children, pregnant women, or other vulnerable populations need additional ethical measures and modified consent processes. Secondary data usage: Retrospective analysis of electronic health records is problematic regarding consent and bias. Anonymization of data and bias reduction measures are vital. Transparency, stakeholder involvement, and scrupulous adherence to global ethical standards—e.g., Declaration of Helsinki and ICH-GCP—are the base. These ensure public confidence is maintained, promotes collaborative work, and culminates in safer therapeutic

Continous Education and Capacity Building: Ongoing education and training are essential to building pharmacovigilance infrastructures and providing safe drug utilization in all healthcare environments. As new therapies, data streams, and regulations emerge, pharmacovigilance experts such as healthcare professionals, pharmacists, regulatory staff, and researchers need ongoing updating of their competencies and skills. Continuous education schemes improve understanding of the mechanisms of reporting adverse drug reactions (ADRs), techniques of risk assessment, and instruments of data analysis. These efforts are especially crucial in low- and middle-income countries, where underreporting and unawareness continue to pose an

important obstacle. Capacity building further encompasses building national centers of excellence, incorporating pharmacovigilance into academic programs, and offering formal training programs like those conducted by the WHO-Uppsala Monitoring Centre. Further, regulatory-academic-industry cooperation facilitates harmonized training models and shared resources. E-learning websites, workshops, and professional certification also facilitate worldwide competency in pharmacovigilance as part of a proactive safety culture, ultimately leading to improved therapeutic outcomes.

Challanges and Limitations:

1. **Underreporting of Adverse Drug Reaction:** Adverse drug reactions (ADRs) are a major global public health issue and lead to a significant proportion of morbidity, mortality, and escalating healthcare expenditure. A critical aspect of pharmacovigilance has been the spontaneous reporting systems (SRS) but underreporting, particularly by patients, continues to mitigate thorough drug safety profiling. The systematic review, in accordance with PRISMA 2020 standards and PROSPERO registered (CRD42021227944), sought to elucidate factors that drive ADR underreporting by patients' systematic literature search of the PubMed and EMBASE databases between January 2006 and November 2022 resulted in 13 studies that qualified for inclusion. These included studies on spontaneous reporting of ADR by patients and investigated the effects of sociodemographic factors, attitudes, and knowledge on reporting.Varied Sources of Information: Patients report subjective, quality-of-life–associated effects, whereas healthcare professionals (HCPs) provide more clinical and objective information. Both sets of information provide complementary benefits to establishing high-quality safety databases Rates of Underreporting: More than 94% are not reported, with patient-reported reports representing only around 9% of all reports in 2014, despite more legal provisions for direct patient reporting (e.g., EU Directive 2010/84/EU and Regulation No. 1235/2010).Barriers to Reporting: Based on Inman's "Seven Deadly Sins" framework (complacency, diffidence, ignorance, indifference, lethargy, financial incentives, fear/guilt), barriers were categorized into:1. Attitudinal barriers – e.g., fear of not being listened to, complacency over known side effects.2. Knowledge gaps – ignorance of where or how to report.3. Practical issues – inadequate reportingsystems, feedback.Excuses/justifications symptoms gone or thought to be non serious impacted reporting probability Quality Assessment: Studies included were assessed using the AXIS tool for cross-sectional studies to ensure methodological quality and low bias.
2. **Data Quality and Completeness:** Successful pharmacovigilance depends considerably on data quality and completeness obtained from multiple sources including spontaneous reporting systems (SRS), electronic health records (EHRs), clinical trials, and real-world evidence (RWE). Yet, the maintenance of high data quality standards continues to be a longstanding issue that impacts the dependability and promptness of safety signal detection and risk assessment.

Key Challenges:

1. Underreporting Adverse Drug Reactions (ADRs):Spontaneous reporting is still the backbone of pharmacovigilance, but research shows that over 90% of ADRs are not reported. This gravely constrains the dataset's completeness and handicaps proper signal detection.
2. Incomplete and Poorly Structured Reports: Most Individual Case Safety Reports (ICSRs) lack essential data fields like dosage, duration, patient history, or outcome .Incomplete reports hinder causality assessment and decrease the value of the data.
3. Inconsistent Terminology and Classification: Inadequate standardization in coding dictionary utilization (e.g., MedDRA, WHO-ART) introduces variability in data input, which impedes aggregation and analysis across jurisdictions and systems.
4. Duplicate and Inconsistent Data: Duplicate entries for one case (multiple reports) or inconsistent data between reporters (e.g., patient versus physician) cause confusion and undermine the pharmacovigilance database's reliability.
5. Delayed or Retrospective Reporting: Delays between the event of an ADR and its reporting can lead to the overlooking of early warning signs, particularly for uncommon or new safety issues.
6. Poor Data from Low-Resource Environments Low-resource environments and developing nations usually do not have strong pharmacovigilance infrastructure, and consequently, there is poor data coverage, particularly in vulnerable or high-risk groups.7. No Interoperability among Systems: Integration across healthcare data systems (e.g., hospital EHRs, claims, national repositories) is commonly fractured, lessening the capability to generate comprehensive safety profiles from diverse data streams.

3. **Limited Integration of Real World Data:** Real-world data (RWD)—from EHRs, insurance claims, and mobile apps—have the potential to greatly improve pharmacovigilance but are not being maximized because of a number of issues. The most prominent are data fragmentation, non-standardization, poor quality data, and the inclusion of unstructured formats. Legal controls like GDPR and HIPAA also restrict the use of cross-border data. Most systems do not have the analytical infrastructure to adequately analyse RWD. Finally, underrepresented groups in RWD bring bias into safety evaluation. In order to address these challenges, efforts such as standardized data models, AI tools, secure data-sharing platforms, and regulatory frameworks are imperative. Better integration of RWD can aid realtime comprehensive drug safety surveillance as well as enhanced patient outcomes worldwide. Advances in computing and health information technology have greatly expanded the sources and availability of biomedical data. The U.S. FDA defines real-world data (RWD) as data relating to patient health and healthcare delivery collected outside of traditional clinical trials, such as through electronic health records (EHRs),

insurance claims, registries, mobile apps, wearable devices, and environmental data. Real-world evidence (RWE) refers to clinical insights gained from analysing RWD.RWD is increasingly being used beyond regulatory drug safety monitoring, drawing interest from pharmaceutical companies, payers, clinicians, policy-makers, and patients. Post-marketing surveillance of drug safety, especially when phase III trials are underpowered for rare adverse events, benefits from RWD—most notably through systems like the FDA's Sentinel Initiative, which integrates EHR, claims, and registry data.

4. **Resources and Capacity Constrains:** One of the most significant challenges for efficient pharmacovigilance is the scarcity of human, technical, and financial resources, especially in LMICs. Even in developed environments, increasing complexity in drug safety information necessitates ongoing investment in skilled workers, sophisticated IT infrastructures, and training programs.Main Limitations: Inadequate Trained Staff: Lack of trained pharmacovigilance workers prevents the identification, evaluation, and reporting of adverse drug reactions (ADRs).Inadequate Funding: Pharmacovigilance initiatives tend to be inadequately funded, resulting in limited outreach, poor reporting systems, and lack of sustainability. Weak Infrastructure: Limited computer access, data integration systems, and signal detection algorithms lower the effectiveness of drug safety monitoring. Low Reporting Culture: In most healthcare organizations, clinicians and pharmacists are either uninformed of pharmacovigilance protocols or do not have incentives and time to report ADRs, further exacerbating capacity. Regulatory Gaps: Some nations are without thorough frameworks or specialized national centers to assist pharmacovigilance activity.

Way Forward: To cross these hurdles, there is a requirement for: Enhancing national pharmacovigilance centers.Spending on manpower training and knowledge initiatives. Utilizing worldwide associations (e.g., WHO-Uppsala Monitoring Centre) Employing digital automation and AI platforms to enhance capacity. It is imperative to address these limitations in order to establish robust, responsive, and anticipatory pharmacovigilance systems globally. Pharmacovigilance within LMICs is considerably undermined by scarce human, technical, and financial resources. There are inadequate trained personnel, and clinicians are typically too busy to submit adverse drug reaction reports (ADRs), and with low public sector incentives, there is high staff turnover. Formal PV training is still limited, though it improves with WHO support and recent curriculum revision within countries such as India. Infrastructure constraints, such as poor IT systems, unstable internet, and a lack of mobile friendly, multilingual ADR reporting instruments, contribute further to a limited level of effectiveness. Economic constraints remain, with the majority of PV programs having no sustainable local funding and depending substantially on foreign donors. Furthermore, most LMICs do not have integrated PV policies or regulatory requirements, leading to patchy systems and weak ADR reporting culture.

Regulatory and legal hedge Pharmacovigilance (PV), according to WHO, is the wisdom and exertion in relation to the discovery, assessment, understanding, and forestallment of adverse medicine responses. Though of significance in the provision of rational and safe medicine use, PV in India is underdeveloped. The Pharmacovigilance Programme of India (PvPI), which was started in the early 21st century, is in its growth phase and encounters several systemic hindrances. The main challenges are executive Obstacles Government backing is pivotal in backing and adding PV outfit. dearths of Healthcare Personnel Underreporting of adverse medicine responses(ADRs) is current with defined PV education, large case cargo, concern about action, and poor mindfulness. tone- drug and Misinformation current tone-drug with the aid of announcements and unreliable internet medicine information plays a significant part in unreported ADRs.Counterfeit and Traditional Medicines shy regulation and poor data on herbal and fake drug hamper safety monitoring. Medicine relations Polypharmacy in HIV/ AIDS and TB complicate identification of malefactor agents. General medicines Despite wide operation, their safety biographies must continue to be covered. Clinical Trials India's increase in clinical trials has not been accompanied by strict monitoring, performing in underreporting of trialrelated ADRs. Regulatory and legal issues greatly hamper the proper functioning of pharmacovigilance systems, particularly in low- and middle- income countries (LMICs). The most critical issues are the absence of overarching laws taking adverse medicine response (ADR) reporting, shy enforcement of current regulations, lack of acceptable legal conditions on assiduity players, and a lack of legal cover for healthcare professionals who report ADRs. These poverties affect in fractured systems, underreporting, and shy data integration. To break down these walls, nations need to have unequivocal laws, apply compliance, match transnational norms (e.g., WHO, ICH), and have legal assurances and impulses for journalists. Bringing nonsupervisory fabrics up to date and integrating digital tools and real- world data is pivotal to enhance medicine safety alert.

WHAT ARE THE CHALLENGES Pharmacovigilance programs are going to encounter some challenges that will affect the country's health situation. Administration Government plays an important part in smooth functioning of the programme. In India, the government is the top stake – holder in the delivery of health care. It's with the help of the public sector; the programme is suitable to reach all niche and corners of the nation. A top source of fund to operate the programme also arrives through government. Therefore, it's maximum with its aid, the programme can not reach the peak. Health Professional shy continuing medical education on pharmacovigilance and deficit of medicine information result in underreporting of adverse medicines events. Croakers feel that utmost of the time they need to report only if the adverse events has casual relationship with the products. In our nation, in view of low croaker - to- case rate, utmost of the events are n't reported because of lack of time, low provocation, ignorance and languor. In malignancy of having trained medical professional in our nation, occasionally croakersare reticent to report because they’re hysterical of being sued and believes reporting would work against them. Lack of training for undergraduates on pharmacovigilance. tone- drug tone- drug is one of the issues

in our nation because people are n't tutored about medicines and they use medicines that are specified by druggist without proper tradition. medicine company announcements and the fluently accessible medicine over-the-counter with available flyers on the cure, suggestion, side- goods make the cases to decide on their own remedial options, without croakeror druggist backing. This results in unlooked-for adverse goods which frequently goes unrefuted and can have negative influence on the society.(5) Web- Grounded drug Web grounded data concerning medicines and conditions without authenticity have been a major challenge to the programme. It results in the unbridled trade of drugs with medicine information of varying degree with questionable safety, efficacity and quality. Fake medicines fake medicines are important and underreported problem, particularly in developing countries. It causes morbidity, mortality, and loss of public confidence in drugs and health structures. The frequence of fake medicines appears to be rising and posed a lesser challenge for the programme in India. It has been to be opposed by close cooperation between medicine companies, governments, or transnational agencies interested in health sector in the developing nation like India.

5. **Challanges in Causality Assessment:** Regulatory and legal factors severely impede the effective operation of pharmacovigilance systems, especially in low- and middle-income countries (LMICs). The most serious among these are the lack of general laws mandating adverse drug reaction (ADR) reporting, weak enforcement of existing laws, insufficient legal mandate on industry actors, and inadequate legal protection for healthcare professionals reporting ADRs. These gaps lead to fragmented systems, underreporting, and poor data integration. In order to dismantle such barriers, countries must have clear laws, make compliance enforceable, align with international standards (e.g., WHO, ICH), and ensure legal guarantees and incentives for reporters. Updating regulatory frameworks by incorporating digital means and real-world evidence is essential to strengthen drug safety vigilance.
6. **Rapid Innovation and New Drug Classes:** The fast speed of pharmaceutical development, particularly with the introduction of new drug categories such as biologics, gene therapies, immunotherapies, and personalized medicines, brings novel and dynamic challenges to pharmacovigilance (PV) systems. Such innovations tend to exceed the capacity of conventional PV systems to monitor, evaluate, and control drug-related risks.

Key Challenges:

Limited Pre-Marketing Safety Data: New medicines, particularly those with accelerated approval, tend to have limited trial data. Infrequent or delayed adverse effects might not be revealed prior to marketing, placing greater dependence on post-marketing surveillance.

1. **Complex Mechanisms of Action:** Emerging drug classes (e.g., monoclonal antibodies, CAR-T cell therapies) possess complex biological interactions, rendering it challenging to anticipate and identify adverse effects by routine PV methodologies.
2. **Emerging Therapeutic Targets:** New medicines tend to target new or intricate biological pathways previously untouched, for which adverse effects could be unknown or poorly understood.
3. **No Historical Data:** with new classes of drugs, there is any historical pharmacovigilance data to use in monitoring safety signals, risk estimation, or regulatory actions.
4. **Difficulties in Causality Evaluation:** Unusual or tardy adverse events from new treatments render it challenging to attribute them causally to a drug, especially when there are no preestablished profiles of reactions. 6.Personalized and Precision Therapeutics: Treatments based on a patient's genetic makeup or biomarker expression require individualized PV approaches and potentially call for incorporating pharmacogenomics information into surveillance models.

7. **Public Misinformation and Vaccine Hesitancy:** Challenges of Public Misinformation and Vaccine Hesitancy in Pharmacovigilance and Drug Safety Public confidence is an essential element in the success of pharmacovigilance (PV) and drug safety programs, particularly for the case of vaccines and mass immunization campaigns. Misinformation and vaccine hesitance are, nonetheless, significant public health threats and PV program effectiveness challenges.

Key Challenges:

Spread of Misinformation: Deceptive rumours regarding adverse effects propagate quickly via social media and messaging and Misinterpretation of initial safety information erodes public trust in regulatory procedures.

1. **Vaccin:** Anxiety about side effects—frequently driven by rumour or exaggerated case reports—results in hesitation or refusal to receive vaccination. Public concerns regarding vaccine safety are more influential than scientific facts, particularly amid emergency rollouts (e.g., COVID-19) 3.Underreporting or Over reporting of Adverse Events: Misinformation will cause both underreporting (because of lack of trust in reporting systems) and over reporting (because of fear or misunderstanding), skewing actual safety profiles.
2. **Deterioration of Trust in Health Authorities:** Conflicting messages from agencies or political leaders decrease credibility.Nontransparent or delayed PV system communication instils suspicion.
3. Challenges in Risk Communication Presenting complex safety information (such as benefit-risk ratios) to a non-scientific audience is challenging. Emotional accounts and individual experiences tend to overwhelm empirical evidence.
4. **Stigma and Social Pressure:** Patients reporting side effects might be stigmatized or dissuaded from reporting. Communities opposed to vaccines might reject contact attempts.

8. **Ethical and Privacy Consideration:** Challenges of Ethical and Privacy Concerns in Pharmacovigilance and Drug Safety. Pharmacovigilance depends on gathering and analysing actual patient experience data, such as adverse drug reactions (ADRs), to maintain drug safety. However, it poses significant ethical and privacy concerns, especially in digital health systems, international data sharing, and growing use of electronic health records (EHRs) and wearable technology.

Major Challenges:

1. Informed Consent Issues: PV systems tend to gather post-marketing safety information in the absence of direct patient consent.Patients may not know their data is being utilized for surveillance. There are ethical issues of concern around autonomy and the right to decide on what is done with one's data.
2. Data Privacy and Confidentiality: Sensitive health information gathered for PV can encompass identifiable data. Risk of breaches of personal data, particularly in systems with poor cybersecurity infrastructure. International data transfer also generates issues regarding compliance with privacy legislation (e.g., GDPR).
3. Balancing Public Health and Individual Rights: There is an ethical conflict between population-level surveillance needs and individual privacy protection. Individual rights can be outweighed by public health benefits without justification or oversight.
4. Transparency and : regarding the use of data, who can access it, and why it is being collected is lost, and this can lead to a loss of trust from the public. Poor communication about handling safety data decreases the inclination to report ADRs.
5. AI and Automated Monitoring AI-powered PV tools can handle vast amounts of personal data with minimal human intervention. Creates concerns around bias, accountability, and fairness of algorithms. Ethical issue around decisions taken by machines instead of healthcare professionals.
6. Fairness in Data Collection and Monitoring Marginalized groups are underrepresented and may distort safety data and decision-making. Ethical issue is raised when advantages of PV are disproportionately available to different populations.
7. Secondary Use of Data: Data gathered for PV could be used for secondary purposes (e.g., marketing, insurance risk stratification) without informing or notifying patients. Ethical and legal limits of secondary use are usually vague or weakly enforced.

CONCLUSION:

Pharmacovigilance is a crucial yet evolving component of India's healthcare system, playing an essential role in ensuring drug safety across the lifecycle of medicines—from development through post-marketing use. Although significant strides have been made globally and nationally through initiatives such as the Pharmacovigilance Programme of India (PvPI), the system still faces multiple challenges including underreporting of adverse drug reactions (ADRs), insufficient integration of real-world data, limited resources, regulatory hurdles, and public misinformation.Emerging technologies such as artificial intelligence, machine learning, and pharmacogenomics offer promising avenues to enhance pharmacovigilance by enabling earlier detection of ADRs, personalized risk assessment, and improved surveillance. However, ethical, legal, and privacy concerns remain substantial barriers that require careful policy design and transparent communication.Ultimately, the success of pharmacovigilance in India and globally hinges on sustained governmental support, stronger infrastructure, continuous education, stakeholder collaboration, and public trust. Overcoming these hurdles will ensure safer drug use, better therapeutic outcomes, and a more resilient healthcare system.

ACKNOWLEDGEMENT:

This work highlights the transformative role of Pharmacovigilance: A pillar of modern drug safety in the field of modern drug discovery and development. The authors—Ms.Korade Payal B.,Dr. Khaire Rahul D., Ms.Kathale Ankita A., Ms. Sankhe Lochani D., Ms. Bhandare Tejashwini S., and Ms.Ghuge Samiksha K. From Pravara Rural Education Society's College of Pharmacy (For Women), Nashik—provide a comprehensive outlook on the future of pharmacovigilance and drug safety is highly dynamic and technology-driven. It promises a more efficient, accurate, and proactive system that moves closer to the individual patient, ultimately enhancing global public health and ensuring the safe use of medicines.

REFERENCE:

1. Shivamurthi T, Dixit DC, Sri Ramachandra M. Review: Pharmacovigilance and drug safety: A global perspective. Asian J Pharm Res Dev. 2025;13(1):152-60.
2. Sharma A, Verma U. Adverse drug reaction monitoring: Current scenario in India. Int J Drug Dev Res. 2013;5(3):1-13.
3. Kumar P, Harugeri A. Role of pharmacovigilance in drug safety system. Perspect Clin Res. 2013;4(1):36-40. doi:10.4103/2229-3485.106398.
4. Liu R, Zhang P. LP-SDA: Code and datasets for "Towards early detection of adverse drug reactions: Combining pre-clinical drug structures and post-market safety reports" [Computer software]. GitHub; 2019. Available from: https://github.com/ruoqi-liu/L
5. Herijgers N, Reeder S-J. Risk management plan optimization following implementation of good pharmacovigilance practices Module V (Revision 2): The Janssen experience. Drug Saf. 2021; 44(11):1211-21.
6. European Medicines Agency. EudraVigilance: EU pharmacovigilance system. In: Wikipedia [Internet]. [cited 2025 Sep 16]. Available from: https://en.wikipedia.org/wiki/EudraVigilance
7. A review article of clinical research studies and pharmacovigilance for healthcare. Highlights how clinical research underpins pharmacovigilance across the drug lifecycle. 2022.
8. Jadhav A, Angadi SS, Naiknaware R, Chavhan R. Enhancing patient safety through pharmacovigilance: Effective monitoring and reporting of adverse drug reactions. Int J Creat Res Thoughts. 2024;12(2):IJCRT2402230. Available from: https://ijcrt.org/papers/IJCRT2402230.pdf
9. Aronson JK. Clinical pharmacology and adverse drug reactions: Understanding mechanisms through pharmacodynamics. Br J Clin Pharmacol. 2010;70(1):3-13.
10. Rosa C, Faich GA. The evolving role of data sources in pharmacovigilance: From spontaneous reports to electronic health

records and literature mining. P T. 2018;43(9):556-62. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6117667/

11. World Health Organization. Module: Adverse events following immunization (AEFI): Monitoring vaccine safety. WHO; 2013. Available from: https://www.who.int/publications/i/item/monitoring-vaccine-safety
12. Muthusamy K. Artificial intelligence and machine learning in pharmacovigilance: Unlocking potential to drive innovation in patient safety. DIA Glob Forum. 2025.
13. Harpaz R, DuMouchel W, Shah NH, Madigan D, Ryan P, Friedman C. Novel data-mining methodologies for adverse drug event discovery and analysis. Clin Pharmacol Ther. 2012;91(6):1010-21. doi:10.1038/clpt.2012.50.
14. Roden DM, McLeod HL, Relling MV, Williams MS, Mensah GA, Peterson JF, Van Driest SL. Pharmacogenomics. Lancet. 2019;394(10197):521-32.
15. European Parliament and Council of the European Union. Regulation (EU) 2016/679 (General Data Protection Regulation). Off J Eur Union. 2016;L119.
16. Weise M, Kurki P, Wolff-Holz E, Bielsky MC, Schneider CK. Biosimilars: The science of extrapolation. Blood. 2014;124(22):3191-6.
23.
17. Hegerius A, Caduff-Janosa P, Savage R, Ellenius J. E-learning in pharmacovigilance: An evaluation of microlearning-based modules developed by the Uppsala Monitoring Centre. Drug Saf. 2020;43:1171-80. doi:10.1007/s40264-020-00981-w.
18. Bahri P, Tsintis A, Behrman RE, Olsson S, Edwards IR, van Hunsel F. Barriers and enablers to patient reporting of adverse drug reactions: A systematic review. Drug Saf. 2023;46(3):245-59.
19. Rudrapatna VA, Butte AJ. Opportunities and challenges in using real-world data for health care. J Clin Invest. 2020;130(2):565-74. doi:10.1172/JCI129197.
20. Makady A, de Boer A, Hillege H, Klungel O, Goettsch W. What is real-world data? A review of definitions based on literature and stakeholder interviews. Value Health. 2017;20(7):858-65.
21. Kumar P, Khan AM. Challenges and opportunities in pharmacovigilance. J Pharmacol Pharmacother. 2013;4(S1):S39-43.
22. Edwards IR, Aronson JK. Adverse drug reactions: Definitions, diagnosis, and management. Lancet. 2000;356(9237):1255-62. doi:10.1016/S0140-6736(00)02799-9.